Gynuity envisions a world in which each individual has access to safe and effective reproductive and maternal health care—delivered where, when, and how needed.
It is our mission to develop scientific, clinical and programmatic evidence in reproductive and maternal health and to advocate for its use, assuring that each individual benefits from the fruits of medical science and technology. We do this on a global scale through research, strategic partnerships, and communications for impact.
Gynuity listens to women, providers and policymakers, and works with them to create services that are safe, high quality, and person-centered. Through conversations and active collaborations, we use research to fill evidence gaps for new models of care, influence change, and advocate for improvements in policy and practice.
Our research demonstrates that simple, safe, and effective reproductive and maternal health technologies transform lives and improve outcomes for women and girls.
Through speaking, convening partners, and publishing our research, we create the synergies that trigger change in policy and practice.
Strategic communications increase the impact of our research and programmatic findings.
Gynuity Celebrates Decision by the U.S. Food and Drug Administration to Loosen Regulations on Mifepristone
A Descriptive Analysis of Medical Abortion Commodity Availability and Pricing at Retail Outlets in 44 Countries Across Four Regions Globally
The Induction With Foley OR Misoprostol (INFORM) Study Dataset. A Dataset of 602 Women With Hypertensive Disease in Pregnancy, in India, Randomised to Either Foley Catheter or Oral Misoprostol for Induction of Labour
Analytical Comparison of Pregnancy-Associated Plasma Protein-A (PAPP-A) Immunoassays for Biochemical Determination of Gestational Age
Ilana Dzuba, Senior Director at Gynuity, chats with media editor of the medical journal Contraception about research Gynuity and partners undertook on later first trimester medical abortion. Their conversation pivots on an award-winning article.Listen to the Podcast (16 minutes)
This toolkit provides resources for providers and health care systems to introduce service delivery that allows people choosing medical abortion the option to receive an implant or injectable contraceptive at the same time as mifepristone.View Toolkit
Gynuity views mifepristone abortion as a revolutionary technology with the potential to increase autonomy and choice in the reproductive realm. Here we reflect on our work to increase medical abortion access.View Reflections
Learn about Gynuity's achievements and new programmatic directions.Read the Strategic Plan
TeleAborto is our research project in Mexico on the provision of medical abortion services using telemedicine -- TeleAborto es nuestro proyecto de investigación en México sobre la prestación de servicios de aborto con medicamentos utilizando la telemedicina. Email/Correo Electrónico: TeleAborto@gynuity.orgVisit the TeleAborto website (in Spanish only) / Visite el sitio web (solo en español)
Gynuity's image bank offers illustrations that can help articulate concepts across audiences. Available for download.View the Image Bank
Discover where to find quality assured medical abortion products.Explore the Database
Gynuity has been at the forefront of global women’s health since 2003.See our Achievements
This short film on the history of mifepristone policy in the U.S. investigates baseless FDA restrictions and claims that overstate the danger of the drug. It is a great refresher on the many barriers to medical abortion access and the burden this puts onto abortion-seekers and care providers. The film features Gynuity president Beverly Winikoff.View Video
As part of a podcast series on Self-Managed Abortion, Gynuity president Beverly Winikoff offers her insights on mifepristone – Part 3: The Abortion Pill, RU486Listen to the Podcast